1. Patients willing and able to provide voluntary written informed consent and to <br/ >follow the protocol requirements <br/ > <br/ >2. Male or female patients between 18 and 60 years of age (both inclusive) <br/ > <br/ >3. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal and/or <br/ >oropharyngeal swabs (sample collected â?¤5 days prior to randomization) <br/ >Note: If rapid antigen test has been performed and patient found positive then <br/ >RT-PCR will be performed prior to randomization <br/ > <br/ >4. Patients with mild COVID-19 and have following symptoms and signs prior <br/ >to randomization <br/ >Upper respiratory tract symptoms (&/or fever) without shortness of breath or <br/ >hypoxia <br/ > <br/ >5. Patients who are able to consume oral medications <br/ > <br/ >6. Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: <br/ >Refrain from donating sperm, and either abstain from sexual intercourse as <br/ >their preferred and usual lifestyle (abstinent on a long term and persistent <br/ >basis) and agree to remain abstinent, or must agree to use contraception <br/ > <br/ >7. Females who are not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of child bearing potential (WOCBP), or is a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user dependent method in combination with barrier <br/ >method), or be abstinent from sexual intercourse as their preferred and usual <br/ >lifestyle (abstinent on a long-term and persistent basis) for 28 days from the <br/ >start of study intervention, a WOCBP must have a negative highly sensitive <br/ >pregnancy test (urine or serum test is required) within 24 hours before the first <br/ >dose of study intervention

1. Patients willing and able to provide voluntary written informed consent and to <br/ >follow the protocol requirements <br/ > <br/ >2. Male or female patients between 18 and 60 years of age (both inclusive) <br/ > <br/ >3. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal and/or <br/ >oropharyngeal swabs (sample collected â?¤5 days prior to randomization) <br/ >Note: If rapid antigen test has been performed and patient found positive then <br/ >RT-PCR will be performed prior to randomization <br/ > <br/ >4. Patients with mild COVID-19 and have following symptoms and signs prior <br/ >to randomization <br/ >Upper respiratory tract symptoms (&/or fever) without shortness of breath or <br/ >hypoxia <br/ > <br/ >5. Patients who are able to consume oral medications <br/ > <br/ >6. Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: <br/ >Refrain from donating sperm, and either abstain from sexual intercourse as <br/ >their preferred and usual lifestyle (abstinent on a long term and persistent <br/ >basis) and agree to remain abstinent, or must agree to use contraception <br/ > <br/ >7. Females who are not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of child bearing potential (WOCBP), or is a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user dependent method in combination with barrier <br/ >method), or be abstinent from sexual intercourse as their preferred and usual <br/ >lifestyle (abstinent on a long-term and persistent basis) for 28 days from the <br/ >start of study intervention, a WOCBP must have a negative highly sensitive <br/ >pregnancy test (urine or serum test is required) within 24 hours before the first <br/ >dose of study intervention

1. Patients willing and able to provide voluntary written informed consent and to <br/ >follow the protocol requirements <br/ > <br/ >2. Male or female patients between 18 and 60 years of age (both inclusive) <br/ > <br/ >3. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal and/or <br/ >oropharyngeal swabs (sample collected â?¤5 days prior to randomization) <br/ >Note: If rapid antigen test has been performed and patient found positive then <br/ >RT-PCR will be performed prior to randomization <br/ > <br/ >4. Patients with mild COVID-19 and have following symptoms and signs prior <br/ >to randomization <br/ >Upper respiratory tract symptoms (&/or fever) without shortness of breath or <br/ >hypoxia <br/ > <br/ >5. Patients who are able to consume oral medications <br/ > <br/ >6. Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: <br/ >Refrain from donating sperm, and either abstain from sexual intercourse as <br/ >their preferred and usual lifestyle (abstinent on a long term and persistent <br/ >basis) and agree to remain abstinent, or must agree to use contraception <br/ > <br/ >7. Females who are not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of child bearing potential (WOCBP), or is a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user dependent method in combination with barrier <br/ >method), or be abstinent from sexual intercourse as their preferred and usual <br/ >lifestyle (abstinent on a long-term and persistent basis) for 28 days from the <br/ >start of study intervention, a WOCBP must have a negative highly sensitive <br/ >pregnancy test (urine or serum test is required) within 24 hours before the first <br/ >dose of study intervention

1. Patients willing and able to provide voluntary written informed consent and to <br/ >follow the protocol requirements <br/ > <br/ >2. Male or female patients between 18 and 60 years of age (both inclusive) <br/ > <br/ >3. Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal and/or <br/ >oropharyngeal swabs (sample collected â?¤5 days prior to randomization) <br/ >Note: If rapid antigen test has been performed and patient found positive then <br/ >RT-PCR will be performed prior to randomization <br/ > <br/ >4. Patients with mild COVID-19 and have following symptoms and signs prior <br/ >to randomization <br/ >Upper respiratory tract symptoms (&/or fever) without shortness of breath or <br/ >hypoxia <br/ > <br/ >5. Patients who are able to consume oral medications <br/ > <br/ >6. Males agree to the following during the intervention period and for at least 90 days after the last dose of study intervention: <br/ >Refrain from donating sperm, and either abstain from sexual intercourse as <br/ >their preferred and usual lifestyle (abstinent on a long term and persistent <br/ >basis) and agree to remain abstinent, or must agree to use contraception <br/ > <br/ >7. Females who are not pregnant or breastfeeding, and at least one of the following conditions applies: Is not a woman of child bearing potential (WOCBP), or is a WOCBP and using a contraceptive method that is highly effective (a low user dependency method OR a user dependent method in combination with barrier <br/ >method), or be abstinent from sexual intercourse as their preferred and usual <br/ >lifestyle (abstinent on a long-term and persistent basis) for 28 days from the <br/ >start of study intervention, a WOCBP must have a negative highly sensitive <br/ >pregnancy test (urine or serum test is required) within 24 hours before the first <br/ >dose of study intervention